Doubly radiolabeled liposomes for pretargeted radioimmunotherapy.
Identifieur interne : 002765 ( Main/Exploration ); précédent : 002764; suivant : 002766Doubly radiolabeled liposomes for pretargeted radioimmunotherapy.
Auteurs : RBID : pubmed:17592745English descriptors
- KwdEn :
- Animals, Arginine (chemistry), Drug Delivery Systems, Drug Stability, Female, Indicators and Reagents, Indium Radioisotopes, Iodine Radioisotopes, Isotope Labeling, Liposomes (chemistry), Liposomes (pharmacokinetics), Mice, Mice, Inbred BALB C, Radioimmunotherapy, Succinimides (chemistry), Tissue Distribution.
- MESH :
- chemical , chemistry : Arginine, Liposomes, Succinimides.
- chemical , pharmacokinetics : Liposomes.
- Animals, Drug Delivery Systems, Drug Stability, Female, Indicators and Reagents, Indium Radioisotopes, Iodine Radioisotopes, Isotope Labeling, Mice, Mice, Inbred BALB C, Radioimmunotherapy, Tissue Distribution.
Abstract
The aim of this study was to design liposomes as radioactivity carriers for pretargeted radioimmunotherapy with favorable pharmacokinetic parameters. To monitor the liposomes integrity in vivo, their surface was radiolabeled with indium-111 bound to DTPA-derivatized phosphatidylethanolamine (DSPE-DTPA) and the aqueous phase was labeled by using an original active loading technique of radioiodinated Bolton-Hunter reagent (BH) that reacts with pre-encapsulated arginine to form a positively charged conjugate ((125)I-BH-arginine). Different formulations of doubly radiolabeled liposomes were tested in vitro and in vivo to evaluate radiolabeling stability, integrity of the vesicles and their pharmacokinetics. Radiolabeling yields were high (surface >75%, encapsulation >60%) and stable (>85% after 24 h in serum 37 degrees C). In vivo, the pharmacokinetic behavior of doubly radiolabeled liposomes was strongly dependant on the formulation. Blood clearance of PEGylated liposomes (DSPC/Chol/DSPE-DTPA/DSPE-PEG5%) was 0.15 mL/h compared to a conventional formulation (DSPC/Chol/DSPE-DTPA: clearance 1.44 mL/h). Non-encapsulated BH-arginine conjugate was quickly eliminated in urine (clearance 6.04 mL/h). Blood kinetics of the two radionuclides were similar and radiochromatographic profiles of mice serum confirmed the integrity of circulating liposomes. The significant reduction of activity uptake in organs after liposome catabolism (liver and spleen), achieved by the rapid renal elimination of (125)I-BH-arginine, should bring significant improvements for targeted radionuclide therapy with sterically-stabilized liposomes.
DOI: 10.1016/j.ijpharm.2007.05.024
PubMed: 17592745
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Doubly radiolabeled liposomes for pretargeted radioimmunotherapy.</title><author><name sortKey="Mougin Degraef, M" uniqKey="Mougin Degraef M">M Mougin-Degraef</name><affiliation wicri:level="3"><nlm:affiliation>Département de recherche en cancérologie, INSERM, U601, Université de Nantes, 9 quai Moncousu 44093, Nantes Cedex 1, France. marie.mougin@nantes.inserm.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département de recherche en cancérologie, INSERM, U601, Université de Nantes, 9 quai Moncousu 44093, Nantes Cedex 1</wicri:regionArea><placeName><region type="region" nuts="2">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Bourdeau, C" uniqKey="Bourdeau C">C Bourdeau</name></author><author><name sortKey="Jestin, E" uniqKey="Jestin E">E Jestin</name></author><author><name sortKey="Sai Maurel, C" uniqKey="Sai Maurel C">C Saï-Maurel</name></author><author><name sortKey="Bourgeois, M" uniqKey="Bourgeois M">M Bourgeois</name></author><author><name sortKey="Saec, P Remaud Le" uniqKey="Saec P">P Remaud-Le Saëc</name></author><author><name sortKey="Thedrez, P" uniqKey="Thedrez P">P Thédrez</name></author><author><name sortKey="Gestin, J F" uniqKey="Gestin J">J-F Gestin</name></author><author><name sortKey="Barbet, J" uniqKey="Barbet J">J Barbet</name></author><author><name sortKey="Faivre Chauvet, A" uniqKey="Faivre Chauvet A">A Faivre-Chauvet</name></author></titleStmt><publicationStmt><date when="2007">2007</date><idno type="doi">10.1016/j.ijpharm.2007.05.024</idno><idno type="RBID">pubmed:17592745</idno><idno type="pmid">17592745</idno><idno type="wicri:Area/Main/Corpus">002759</idno><idno type="wicri:Area/Main/Curation">002759</idno><idno type="wicri:Area/Main/Exploration">002765</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Arginine (chemistry)</term><term>Drug Delivery Systems</term><term>Drug Stability</term><term>Female</term><term>Indicators and Reagents</term><term>Indium Radioisotopes</term><term>Iodine Radioisotopes</term><term>Isotope Labeling</term><term>Liposomes (chemistry)</term><term>Liposomes (pharmacokinetics)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Radioimmunotherapy</term><term>Succinimides (chemistry)</term><term>Tissue Distribution</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Arginine</term><term>Liposomes</term><term>Succinimides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Liposomes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Drug Delivery Systems</term><term>Drug Stability</term><term>Female</term><term>Indicators and Reagents</term><term>Indium Radioisotopes</term><term>Iodine Radioisotopes</term><term>Isotope Labeling</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Radioimmunotherapy</term><term>Tissue Distribution</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this study was to design liposomes as radioactivity carriers for pretargeted radioimmunotherapy with favorable pharmacokinetic parameters. To monitor the liposomes integrity in vivo, their surface was radiolabeled with indium-111 bound to DTPA-derivatized phosphatidylethanolamine (DSPE-DTPA) and the aqueous phase was labeled by using an original active loading technique of radioiodinated Bolton-Hunter reagent (BH) that reacts with pre-encapsulated arginine to form a positively charged conjugate ((125)I-BH-arginine). Different formulations of doubly radiolabeled liposomes were tested in vitro and in vivo to evaluate radiolabeling stability, integrity of the vesicles and their pharmacokinetics. Radiolabeling yields were high (surface >75%, encapsulation >60%) and stable (>85% after 24 h in serum 37 degrees C). In vivo, the pharmacokinetic behavior of doubly radiolabeled liposomes was strongly dependant on the formulation. Blood clearance of PEGylated liposomes (DSPC/Chol/DSPE-DTPA/DSPE-PEG5%) was 0.15 mL/h compared to a conventional formulation (DSPC/Chol/DSPE-DTPA: clearance 1.44 mL/h). Non-encapsulated BH-arginine conjugate was quickly eliminated in urine (clearance 6.04 mL/h). Blood kinetics of the two radionuclides were similar and radiochromatographic profiles of mice serum confirmed the integrity of circulating liposomes. The significant reduction of activity uptake in organs after liposome catabolism (liver and spleen), achieved by the rapid renal elimination of (125)I-BH-arginine, should bring significant improvements for targeted radionuclide therapy with sterically-stabilized liposomes.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17592745</PMID><DateCreated><Year>2007</Year><Month>10</Month><Day>01</Day></DateCreated><DateCompleted><Year>2008</Year><Month>01</Month><Day>16</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0378-5173</ISSN><JournalIssue CitedMedium="Print"><Volume>344</Volume><Issue>1-2</Issue><PubDate><Year>2007</Year><Month>Nov</Month><Day>1</Day></PubDate></JournalIssue><Title>International journal of pharmaceutics</Title><ISOAbbreviation>Int J Pharm</ISOAbbreviation></Journal><ArticleTitle>Doubly radiolabeled liposomes for pretargeted radioimmunotherapy.</ArticleTitle><Pagination><MedlinePgn>110-7</MedlinePgn></Pagination><Abstract><AbstractText>The aim of this study was to design liposomes as radioactivity carriers for pretargeted radioimmunotherapy with favorable pharmacokinetic parameters. To monitor the liposomes integrity in vivo, their surface was radiolabeled with indium-111 bound to DTPA-derivatized phosphatidylethanolamine (DSPE-DTPA) and the aqueous phase was labeled by using an original active loading technique of radioiodinated Bolton-Hunter reagent (BH) that reacts with pre-encapsulated arginine to form a positively charged conjugate ((125)I-BH-arginine). Different formulations of doubly radiolabeled liposomes were tested in vitro and in vivo to evaluate radiolabeling stability, integrity of the vesicles and their pharmacokinetics. Radiolabeling yields were high (surface >75%, encapsulation >60%) and stable (>85% after 24 h in serum 37 degrees C). In vivo, the pharmacokinetic behavior of doubly radiolabeled liposomes was strongly dependant on the formulation. Blood clearance of PEGylated liposomes (DSPC/Chol/DSPE-DTPA/DSPE-PEG5%) was 0.15 mL/h compared to a conventional formulation (DSPC/Chol/DSPE-DTPA: clearance 1.44 mL/h). Non-encapsulated BH-arginine conjugate was quickly eliminated in urine (clearance 6.04 mL/h). Blood kinetics of the two radionuclides were similar and radiochromatographic profiles of mice serum confirmed the integrity of circulating liposomes. The significant reduction of activity uptake in organs after liposome catabolism (liver and spleen), achieved by the rapid renal elimination of (125)I-BH-arginine, should bring significant improvements for targeted radionuclide therapy with sterically-stabilized liposomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mougin-Degraef</LastName><ForeName>M</ForeName><Initials>M</Initials><Affiliation>Département de recherche en cancérologie, INSERM, U601, Université de Nantes, 9 quai Moncousu 44093, Nantes Cedex 1, France. marie.mougin@nantes.inserm.fr</Affiliation></Author><Author ValidYN="Y"><LastName>Bourdeau</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Jestin</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Saï-Maurel</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Bourgeois</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Saëc</LastName><ForeName>P Remaud-Le</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Thédrez</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Gestin</LastName><ForeName>J-F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Barbet</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Faivre-Chauvet</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>05</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Pharm</MedlineTA><NlmUniqueID>7804127</NlmUniqueID><ISSNLinking>0378-5173</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indicators and Reagents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Iodine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Liposomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Succinimides</NameOfSubstance></Chemical><Chemical><RegistryNumber>65114-37-6</RegistryNumber><NameOfSubstance>Bolton-Hunter reagent</NameOfSubstance></Chemical><Chemical><RegistryNumber>94ZLA3W45F</RegistryNumber><NameOfSubstance>Arginine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Arginine</DescriptorName><QualifierName MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Drug Delivery Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Drug Stability</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indicators and Reagents</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Indium Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Iodine Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Isotope Labeling</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Liposomes</DescriptorName><QualifierName MajorTopicYN="Y">chemistry</QualifierName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radioimmunotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Succinimides</DescriptorName><QualifierName MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2007</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">S0378-5173(07)00457-7</ArticleId><ArticleId IdType="doi">10.1016/j.ijpharm.2007.05.024</ArticleId><ArticleId IdType="pubmed">17592745</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002765 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002765 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:17592745
|texte= Doubly radiolabeled liposomes for pretargeted radioimmunotherapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:17592745" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |